Global Personalized Medicines Industry

Global Personalized Medicines Industry

  • April 2021 •
  • 171 pages •
  • Report ID: 2116899 •
  • Format: PDF
Abstract:
- Global Personalized Medicines Market to Reach $515.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Personalized Medicines estimated at US$227.9 Billion in the year 2020, is projected to reach a revised size of US$515.3 Billion by 2027, growing at aCAGR of 12.4% over the period 2020-2027. Tests & Lab Services, one of the segments analyzed in the report, is projected to record 11.3% CAGR and reach US$296.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Targeted Therapeutics segment is readjusted to a revised 13.9% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $67.2 Billion, While China is Forecast to Grow at 12% CAGR
- The Personalized Medicines market in the U.S. is estimated at US$67.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$90.5 Billion by the year 2027 trailing a CAGR of 12% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.7% and 10.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR.

- Select Competitors (Total 87 Featured) -
  • Abbott Molecular
  • Beckman Coulter, Inc.
  • bioMérieux SA
  • Bristol-Myers Squibb Company
  • Dako Denmark A/S
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Hologic, Inc.
  • Lab 21 Limited
  • Macrogen, Inc.
  • NeoGenomics Laboratories, Inc.
  • Novartis AG
  • QIAGEN NV
  • Rosetta Genomics Ltd.
  • Thermo Fischer Scientific Inc.